Study: Gene-Eden-VIR/Novirin, patented natural antiviral, more effective and safer than leading drugs Acyclovir, Valacyclovir, and Famciclovir

VALLEY COTTAGE, NY, UNITED STATES, September 19, 2016 /EINPresswire.com/ -- The Center for the Biology of Chronic Disease (CBCD) announces the publication of a new paper that reports the results of a clinical study that tested the natural antiviral Gene-Eden-VIR/Novirin in genital herpes. The study showed that Gene Eden-VIR/Novirin safely and effectively decreased the recurrence rate of genital herpes outbreaks. The study also showed that the clinical effects of Gene-Eden-VIR/Novirin are mostly better than those of the leading drugs Acyclovir, Valacyclovir, and Famciclovir. These drugs are widely used as the first-line treatment in viral infections. Surprisingly, the study showed that the natural antiviral Gene-Eden-VIR/Novirin is mostly superior to these drugs. The paper was published in the important medical journal Drug Design, Development and Therapy (1).

The paper can be found on Pubmed.com, at: http://www.ncbi.nlm.nih.gov/pubmed/27621592. Pubmed is a free search engine that includes references and abstracts on life sciences and biomedical subjects. Pubmed is maintained by the United States National Library of Medicine (NLM), at the National Institutes of Health (NIH). A movie that presents Dr. Hanan Polansky and Dr. Edan Itzkovitz discussing the study can be found at https://youtu.be/kJzAYDEEJt0.

According to Dr. Hanan Polansky, "To the best of our knowledge, this is the first time that a dietary supplement was shown to be more effective than the leading drugs in an important drug category."

Gene-Eden-VIR/Novirin consists of five natural ingredients, quercetin, green tea extract, cinnamon extract, licorice extract, and selenium. The Gene-Eden-VIR/Novirin formula is patent protected. The formula was developed to target latent viruses. Gene-Eden-VIR/Novirin was introduced in the marketplace at the end of 2009. A previous clinical study showed that Gene-Eden-VIR/Novirin has antiviral properties (2).

The scientists, who created the Gene-Eden-VIR/Novirin formula, used a unique scientific tool, Computer Intuition, a proprietary psycholinguistic-based, data-mining program that analyzes the text found in scientific papers. The scientists’ objective was to identify natural ingredients that have a strong antiviral effect. To achieve the objective, they used the computer program to analyze more than 50,000 papers. The results of the analysis assisted them in selecting the five ingredients, and their most effective dosages (2).

The study compared the clinical effects of suppressive treatment with Gene-Eden-VIR/Novirin with those reported in published clinical studies that tested Acyclovir, Valacyclovir, and Famciclovir, the three leading drugs approved by the FDA for the treatment of genital herpes. Out of the fifteen tests that compared Gene-Eden-VIR/Novirin to the three drugs, Gene-Eden-VIR/Novirin had superior efficacy in eight tests, inferior efficacy in three tests, and comparable efficacy in four tests. Also, while the three drugs have known side effects, the users of Gene-Eden-VIR/Novirin reported no side effects.

In summary, the paper reports the results of a clinical study that tested the effect of suppressive treatment with Gene-Eden-VIR/Novirin in genital herpes. The study showed that the treatment safely decreased the number of genital herpes outbreaks, and that the clinical effects of Gene-Eden-VIR/Novirin are mostly better than those of Acyclovir, Valacyclovir, and Famciclovir.

About the CBCD
The Center for the Biology of Chronic Disease (CBCD) (http://www.cbcd.net) is a not-for-profit research organization. The CBCD’s mission is to advance the research on the effect of foreign DNA on the public's health, and on treatments for the diseases caused by foreign DNA.

(1) Polansky, H. Javaherian, A. Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and Famciclovir. Drug Design, Development and Therapy 2016:10 2713-2722

(2) Polansky H, Itzkovitz E. Gene-Eden-VIR is antiviral: results of a post marketing clinical study. Pharmacol Pharm. 2013;4(6A):1-8

Mike Davis
The Center for the Biology of Chronic Disease
5852509999
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.